SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-248476
Filing Date
2023-10-02
Accepted
2023-10-02 08:49:29
Documents
12
Period of Report
2023-09-28
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d486037d8k.htm   iXBRL 8-K 39565
  Complete submission text file 0001193125-23-248476.txt   162466

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA syrs-20230928.xsd EX-101.SCH 2844
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE syrs-20230928_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syrs-20230928_pre.xml EX-101.PRE 10808
6 EXTRACTED XBRL INSTANCE DOCUMENT d486037d8k_htm.xml XML 3226
Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 617-744-1340
Syros Pharmaceuticals, Inc. (Filer) CIK: 0001556263 (see all company filings)

IRS No.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37813 | Film No.: 231298046
SIC: 2834 Pharmaceutical Preparations